THE EFFECTS OF TERBIUM ON THE ACCUMULATION OF CISPLATIN IN HUMAN OVARIAN-CANCER CELLS

被引:15
作者
CANADA, RG
ANDREWS, PA
MACK, KM
HAIDER, A
机构
[1] GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007
[2] HOWARD UNIV,SCH LIBERAL ARTS,DEPT MATH,WASHINGTON,DC 20059
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 1995年 / 1267卷 / 01期
关键词
D O I
10.1016/0167-4889(95)00019-O
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this investigation, we report a relationship between the terbium (Tb3+) binding protein and the accumulation of cisplatin in human ovarian cancer cells. The number of Tb3+ binding sites in cisplatin-resistant C13* cells is significantly greater by 79% than those in cisplatin-sensitive 2008 cells. Exposure to Tb3+ also increased the cellular accumulation of cisplatin. The accumulation of cisplatin as a function of the Tb3+ concentration in the C13* cells (0.85%/mu M Tb3+) was significantly greater than the accumulation of cisplatin in 2008 cells with respect to Tb3+ (0.46%/mu M Tb3+). The number of Tb3+ binding sites in revertant RH4 cells was similar to that in 2008 cells. The RH4 cells were less sensitive to the stimulatory effects of Tb3+ than the C13* cells. Our results show that the Tb3+ binding protein correlates with cisplatin resistance, and the receptor binding of Tb3+ increases the accumulation of cisplatin in cisplatin-resistant cells.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 50 条
[21]   DISPOSITION OF UNCHANGED CISPLATIN IN PATIENTS WITH OVARIAN-CANCER [J].
REECE, PA ;
STAFFORD, I ;
DAVY, M ;
FREEMAN, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (03) :320-325
[22]   INTRAPERITONEAL CISPLATIN AND CARBOPLATIN IN THE MANAGEMENT OF OVARIAN-CANCER [J].
MARKMAN, M .
SEMINARS IN ONCOLOGY, 1994, 21 (02) :17-19
[23]   DIFFERENTIAL CYTOTOXICITY OF METAL CHELATING-AGENTS IN CISPLATIN SENSITIVE AND RESISTANT HUMAN OVARIAN-CANCER CELLS [J].
NICHOLSON, DL ;
MAIER, RH ;
PORIES, WJ .
TRACE ELEMENTS IN MEDICINE, 1993, 10 (04) :188-191
[24]   DIFFERENCES IN CISPLATIN-DNA ADDUCT FORMATION IN SENSITIVE AND RESISTANT SUBLINES OF HUMAN OVARIAN-CANCER CELLS [J].
REED, E ;
BEHRENS, B ;
YUSPA, SH ;
POIRIER, MC ;
HAMILTON, T ;
OZOLS, RF .
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 :285-285
[25]   TAXOL SENSITIZES HUMAN OVARIAN-CANCER CELLS TO RADIATION [J].
STEREN, A ;
SEVIN, BU ;
PERRAS, J ;
ANGIOLI, R ;
NGUYEN, H ;
GUERRA, L ;
KOECHLI, O ;
AVERETTE, HE .
GYNECOLOGIC ONCOLOGY, 1993, 48 (02) :252-258
[26]   ESTABLISHMENT OF A CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINE [J].
KIKUCHI, Y ;
MIYAUCHI, M ;
KIZAWA, I ;
OOMORI, K ;
KATO, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1986, 77 (06) :1181-1185
[27]   ALLELOTYPE OF HUMAN OVARIAN-CANCER [J].
SATO, T ;
SAITO, H ;
MORITA, R ;
KOI, S ;
LEE, JH ;
NAKAMURA, Y .
CANCER RESEARCH, 1991, 51 (19) :5118-5122
[28]   HIGH-DOSE CISPLATIN THERAPY IN OVARIAN-CANCER [J].
OZOLS, RF ;
YOUNG, RC .
SEMINARS IN ONCOLOGY, 1985, 12 (04) :21-30
[29]   OVARIAN-CANCER - SECONDARY CISPLATIN REGIMENS AND PROGNOSTIC FACTORS [J].
BRUCKNER, HW ;
COHEN, CJ ;
KABAKOW, B ;
WALLACH, R ;
DEPPE, G ;
RATNER, L ;
BHARDWAJ, S ;
GOLDBERG, JD ;
REISMAN, A ;
HOLLAND, JF .
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR) :469-469
[30]   CISPLATIN IN OVARIAN-CANCER - HOW MUCH AND FOR HOW LONG [J].
UMBACH, GE ;
VONMATTHIESSEN, H ;
FABER, P .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (12) :472-476